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Summary.-Phorbol, the unesterified parent alcohol of the skin promoter TPA, was
administered i.p., twice weekly, throughout the lifetime of mice of 7 inbred strains:
males and females of AKR/J, C3Heb and BALB/c, and females of SJL/J, DBA/2, SWR
and C57BL. A striking difference in strain response was observed, with a pronounced
leukaemogenic effect in SWR, a significant shortening of the latent period for spon-
taneous reticulum cell sarcomas (RCNB) in SJL/J, and no demonstrable effect in the
other strains. When mice of 3 of the above-mentioned strains (SWR, SJL/J and
AKR/J) were thymectomized prior to the beginning of phorbol treatment, different
patterns of response were again observed. Thymectomy did not influence the
leukaemia incidence in SWR mice, slightly inhibited RCNB development in SJL/J
mice and converted phorbol into a leukaemogenic agent for AKR/J mice.
FOLLOWING the establishment of the
two-stage mechanism of skin carcino-
genesis, with croton oil as promoting
agent, a number of attempts have been
made to discover whether a similar
mechanism was operative in tissues other
than skin, and to identify some of the
substances capable of such systemic initi-
ation and promotion (Berenblum, 1975).
In the case of skin, the effective pro-
moter, isolated from croton oil, was
identified as 12-0-tetradecanoyl-phorbol-
13-acetate (TPA) (Hecker, 1968; Van
Duuren, 1969). Though the unesterified
parent alcohol, phorbol, was first claimed
to be entirely inlactive as promoter for
skin carcinogenesis (Hecker, 1966), and
subsequently found to possess weak or
borderline promoting action for this tissue,
under special conditions (Baird and Bout-
well, 1971; Armuth and Berenblum, 1976),
it proved to be an effective promoter for
lung, liver and mammary carcinogenesis
(Armuth and Berenblum, 1972, 1974).
In the course of these studies on
systemic promoting action, it was found
that phorbol was also a potent leukae-
mogenic agent, producing non-thymic
leukaemia in SWR mice (Berenblum and
Lonai, 1970) and thymic lymphomas in
Wistar rats (Armuth and Berenblum,
1974).
Since strain differences in response to
systemic carcinogenesis are known to be
sometimes quite pronounced (Weisburger
and Weisburger, 1967), and also in
leukaemogenesis (Upton and Furth, 1957),
it was decided to test the leukaemogenic
action of phorbol in a number of different
strains of mice. (An additional reason
for undertaking this was to form a basis
for the projected testing of a series of
phorbol derivatives under standardized
conditions.)
When major differences in response to
phorbol leukaemogenesis were observed
in the experiment, 3 of the strains were
chosen for further observation, involving
thymectomy in untreated and phorbol-
injected animals.
MATERIALS AND METHODS
Seven inbred strains of specific-pathogen-
free mice from the Institute's Breeding
Centre-w.Nere used in the present experiment:LEUKAEMOGENESIS BY PHORBOL IN MOUSE STRAINS
male andfemaleAKR/J, C3Heb and BALB/c,
and female SWR, SJL/J, DBA/2 and C57BL.
The mice were kept in metal cages, 10 per
cage, in an air-conditioned room at 21-25°C
and were fed Purina laboratory chow and tap
water ad libitum.
The mice were checked daily and
examined more thoroughly twice weekly.
Moribund animals and those showing signs of
leukaemia were killed and autopsied, together
with those occasionally found dead. Spleen,
liver, lymph nodes, kidneys and thymus were
taken routinely for histological examination,
fixed in Bouin's solution, embedded in
paraffin and stained with haematoxylin and
eosin.
Phorbol, kindly supplied by Prof. E.
Hecker, was made up as a 5-mM solution in
phosphate-buffered saline. Twice weekly i.p.
injections of 0-2 ml each were given until the
end of the experiment (364,ug/mouse/injec-
tion). Treatment started when the animals
were 6-8 weeks old.
Separate groups of female SWR and
SJL/J mice as well as male and female
AKR/J mice were thymectomized under
ether anaesthesia and were later divided into
two subgroups: one serving as untreated
control, the other being treated as above,
twice weekly, by i.p. injections of phorbol,
throughout their lifetime, the treatment
beginning at the age of 6-8 weeks.
In the case of SWR and SJL/J mice,
thymectomy was performed one week before
the beginning of phorbol injections, while
AKR/J mice were thymectomized as young
adults at less than one month of age, to
ensure that no thymus-processed preleu-
kaemic cells were present at the time of the
experiment (Haran-Ghera, personal communi-
cation). During autopsies and histological
examinations, special attention was paid to
any remnants of thymic tissue, and where
there was the slightest indication ofsuch, the
animals were discarded from the results.
In evaluating the results, comparison was
TABLE I.-Incidence of Lymphoreticular Diseases in Different Mouse Strains
after Treatment with Phorbol
Initial Average
number of Incidence in
Strain Sex Treatment animals effective totala
C3Heb M - 50 0/41 =0%
M Phorbolc 60 0/59=0%
F 65 0/61 =0/o
F Phorbolc 50 0/46=0/o
BALB/c M - 60 0/58=0%
M Phorbolc 48 0/41 =0%
F 60 0/53=0%
F Phorbolc 70 0/68=0%
DBA/2 F ? 2%d
F Phorbolc 40 3/39= 7%
C57BL F 20 0/20=0%
F Phorbolc 30 0/30=0%
F 2 x 170 R 20 7/20=35%e
F 2 x 170 R+Phorbo1c 30 15/30=50%e
SW.R F 45 3/45 = 6%f
F Phorbole 40 29/39=74%
SJL/J F 35 26/32=81%g
F Phorbolc 40 27/33=82%9
AKR/J M 18 10/14=71%e
M Phorbolc 18 11/14=79%e
F 16 15/15= 100%e
F Phorbolc 17 11/13=85%C
a Effective total = number of mice at the appearance of first tumour in the experiment.
b In days from birth.
c 0-2 ml of 5 mM solution, i.p., twice weekly, throughout lifetime.
d Weisburger and Weisburger (I 967).
e Thymic lymphatic leukaemia.
f Non-thymic lymphatic leukaemia.
g Reticulum cell sarcoma Type B.
latent
periodb
?
259
197
286
291
216
393
284
304
298
324
279
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Fic. 1. RCNB in intact and thymectomized female SJLIJ mice, with and without phorbol treatment.
(a) . 0 phorbol-treated; (b) 0 O untreated controls; (c) A A thymectomized,
phorbol-treated; (d)A A A thymectomized.
made between the leukaemia incidences in
intact and phorbol-treated, as well as in
intact and thymectomized mice, the x2 test
being used for the determination ofstatistical
significance.
RESULTS
A. Leukaemogenesis
The leukaemogenic effect of phorbol in
SWR mice-the only strain which re-
sponded strongly has alreadv been re-
portedearlier (Berenblum andLonai, 1.970),
and was now confirmed in a repeat
experiment: 29/39 (740o) of the mice
developing lymphatic leukaemias as a
result of phorbol treatment, with an
average latent period of 216 days from
birth (Table I). Of these, only 3 mice
showed thymic involvement, according to
the macro-and microscopic examination.
Inthe case ofSJL/J mice, no lymphatic
leukaemias were induced by chronic
phorbol treatment, but the spontaneous
development of reticulum cell neoplasms
type B (RCNB), characteristic of the
strain, was significantly enhanced, as
shown by the shortening of the latent
period (Fig. 1). The actual figures for
cumulative incidence were: in the un-
treated controls 23/32 (81%: average
latent period 393 days from birth) and in
the phorbol-injected animals 27/33 (82%:
average latent period 284 days). From
Fig. 1, it can be seen that 5000 mortality
caused by reticulum cell sarcomas was
advanced by 3 months in the phorbol-
treated group, as compared to the un-
treated controls.
C57BL mice did not respond to phorbol
treatment with leukaemia development
(Table 1), and the spontaneous leukaemia
incidence was also 000. Some of the mice
received 2 x 170 rad whole body X-
irradiation, in an attempt to breakthrough
the immunological barrier of this strain,
but even in this case no significant excess
of leukaemias could be detected with X-
irradiation plus phorbol treatment, com-
pared to X-irradiation only (0.20 < P <
0.30) (Table I).
In AKR/J mice, the spontaneous
lymphatic leukaemia incidence was al-
ready high (15/15 100% in females,
with an average latent period of 324 days
from birth, and 10/14 71% in males,
with a latent period of304days). Phorbol
did not alter either the incidence or the
latent period of the leukaemias. As sum-
marized in Table I, phorbol-treated
females developed thymic lymphatic leu-
kaemias in 11/13 (85%: latent period 279
days) and males in 11/14 (790o: latent
period 298 days), respectively. Similar
results have been reported in an earlier
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experiment (Armuth and Berenblum,
1972).
No lymphoreticular diseases of any
kind developed, during more than a year's
observation, in C3Heb, BALB/c and
DBA/2 mice, in response to phorbol
(Table I). The spontaneous occurrence
of leukaemias in these strains is also very
low or non-existent.
B. Effect ofthymectomy
Thymectomy prior to phorbol treat-
ment did not alter the pattern of leukae-
mia induction in SWR mice. In the
thymectomized phorbol-treated group, 32
mice out of 38 (84%) developed lymphatic
leukaemias, as against the 74% incidence
in intact mice. Four additional cases of
myeloid leukaemia (11%) and two ofretic-
ulum cell sarcoma (5%) were observed.
Fig. 2 shows the rate of leukaemia de-
velopment in these 2 groups. Judging
from the shape of the curves, a difference
in leukaemia development between the
thymectomized and non-thymectomized
mice might be suggested, but the total
incidences were nearly the same, and the
average latent periods did not differ either.
In SJL/J mice, thymectomy affected
RCNB development both in the untreated
and in the phorbol-treated group (Fig. 1).
Thymectomized SJL/J mice developed
RCNB in 59% (16/27) with an average
latent period of 407 days against 81%
(26/32) in the intact controls (latent
2 50
u
2 30 0
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150 200 250
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Fia. 2.-Phorbol-induced leukaemia in intact
and thymectomized SWR mice. O O
intact; * * thymectomized.
period 393 days). The incidence in the
phorbol-treated group was influenced the
same way. While in the intact mice after
phorbol treatment 82% of the animals
(27/33) developed RCNB (average latent
period 284 days), thymectomy one week
prior to the beginning of the treatment
reduced this incidence to 56% (19/34:
average latent period 341 days). This
inhibitory effect cannot, however, be
considered significant (0.05 < P < 0-10
for the untreated and P , 0.02 for the
phorbol-treated groups, respectively).
Thymectomy at an early age (less than
onemonth)decreasedthehigh spontaneous
incidence of lymphatic leukaemias in
AKR/J mice from 100% for females and
TABLE II.-Leukaemia Incidences in Intact and in Thymectomized AKR/J Mice with
and without Phorbol Treatment
Females
r - j 5
Intact Thymectomized
15/15 =100%a 4/14=29%b
(324 days) (514 days)
11/13 =85%a
(279 days)
7/13=54%b
(395 days)
3/13=23%c
(493 days)
Males
Intact Thymectomized
10/14= 71%a 3/27= 11%b
(304 days) (432 days)
1/27 =4%c
(413 days)
11/14=79%a 14/20=70%b
(298 days) (451 days)
1/20=50/c
(354 days)
a Thymic lymphatic leukaemia.
b Non-thymic lymphatic leukaemia.
c Myeloid leukaemia.
Significance of differences in leukaemia incidence in untreated and phorbol-treated;
females: 0.10 < P < 0-20; males: P << 0-001.
Without phorbol
With phorbol
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FIG. 3. Lymphatic leukaemia in AKR/J mice. C Y, d: untreated; P X, ,: phorbol-treated;
Tx X, d: thymectomized; Tx + P Y, S: thymectomized, phorbol-treated.
71% for males to 29% and 11% respec-
tively. There was also a lengthening of
the average latent periods from 324-304
days of age to 514-432 days (Table II).
In the intact AKR/J mice, phorbol treat-
ment did not alter the pattern of (spon-
taneous) leukaemia development, either in
terms of incidence or with respect to the
average latent periods. Table II and
Fig. 3 show, however, that thymectomized
mice of this strain, especially the males,
responded fairly wellto continuous phorbol
treatment, with an increased incidence of
leukaemias from 29% and 11% to 54%
and 70% in the respective sex groups.
The leukaemias developing in thy-
mectomized AKR/J mice were mostly
lymphatic, although no traces of thymic
tissue could be found either by gross
examination or microscopically. Three
additional myeloid leukaemias developed
in the phorbol-treated females, and one
case each in the untreated and phorbol-
injected males.
DISCUSSION
The crucial outcome of this enquiry
is the fact that phorbol is so potent a
leukaemogenic agent for SWR mice, but
almost entirely devoid of such action in
the other strains of mice tested. In
trying to find an explanation for this, it is
worth examining how these various strains
respond to other forms of leukaemogenic
action.
Strains C3Heb and BALB/c are known
to respond poorly to chemical leukaemo-
genesis (Upton and Furth, 1957), thus
paralleling theresults withphorbol (though
in the latter case, the response was com-
pletely negative). No such parallelism
seems to exist for the other strains tested.
In the case of C57BL mice, X-irradia-
tion is a very effective inducer ofleukaem-
ias (Kaplan, 1964), while urethane can also
act as a leukaemogenic agent (Doell and
Carnes, 1962). Yet phorbol treatment did
not reveal any leukaemogenic activity in
this strain. In one group, the phorbol-
treated mice were also irradiated, taking
into account the known immunosuppres-
sive properties as well asthe leukaemogenic
action of X-irradiation in this strain. Its
combination with phorbol did not, how-
ever, significantly increase the incidence
of radiation-induced leukaemias. Thus
the possibility of syncarcinogenic action
between these two factors can be excluded.
DBA/2 mice, which reveal no spon-
taneous leukaemia incidence, are never-
theless susceptible to lymphoma induction
both by chemical carcinogens and X-
irradiation (Chen and Berenblum, 1968).
The failure of phorbol to produce leukae-
mia in this strain is therefore yet another
example ofhow critical the choice ofstrain
is in relation to different carcinogens.
Go,~~~~~x
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TABLE III.-Predominance of Different Cell Types in SJL/J Reticulum
Cell Sarcomas
Lymphocyte Reticulum cell Giant cell Plasma c4
Untreated controls 20/32=630o 5/32= 150% 3/32=9% 4/32= 12
Phorbol treated 15/34=400o
SJL/J mice, which are genetically
closely related to SWR mice, are known to
develop, at a relatively early age, spon-
taneous reticulum cell sarcomas of B type
(RCNB) (Dunn, 1954). Dimethylbenzan-
thracene feeding induces lymphosarcomas
in this strain, while X-irradiation produces
either lymphatic or myeloid leukaemias,
depending on the dose and the schedule of
irradiation (Haran-Ghera, Kotler and
Meshorer, 1967). In the present experi-
ment, i.p. phorbol injections caused no
more than an acceleration of RCNB
development. Histological examination
of each case showed that the proportion of
plasma cells in the tumours of phorbol-
injected mice had increased significantly
(Table III), thus suggesting a mechanism
similar to that ofi.p. mineral oil injections
(Ben-Yaakov, 1974).
In AKR/J mice, phorbol treatment did
not affect the pattern of spontaneous
(viral) leukaemia development: analogous
to the results of Gericke, Kovac and
Hecker (1974), who failed to induce
leukaemias by i.p. phorbol administration
in their AKR subline, in which spon-
taneous leukaemia incidence is extremely
low.
There are many known examples of
species and even strain differences in
response to carcinogenic stimuli, attribut-
able to different pathways of metabolizing
the compound or to a detoxication process
in one species and its lack in others
(Weisburger and Williams, 1975), with
evidence of corresponding variations in
enzyme activity (Kuori, Ratrie and Whit-
mire, 1973). Unfortunately, there is no
information of this kind available about
the metabolic fate of phorbol.
The 3 strains for thymectomy were
chosen because oftheir strikingly different
response to phorbol treatment. In SWR
3/34=9%
ell
2%,
P<0-01
1/34=3% 15/34=44%
mice, the results confirmed previous
morphological evidence that the thymus
did not take part in the induction and
development of the leukaemias. The
suggested explanation is that only bone-
marrow-derived lymphocytes participate
in this form of leukaemogenesis (Haran-
Ghera and Peled, 1973; Dexter et al.,
1974).
In the SJL/J mice, thymectomy pos-
sibly had a slight inhibitory effect in both
the control and the phorbol-treated mice,
the resitlts corresponding well with
previous findings by Haran-Ghera et al.,
(1967). The lack of a real inhibition by
thymectomy suggests a mechanism, pro-
posed by Lamon et al. (1973), that immune
surveillance is a function of non-thymus-
derived cells, or that it is a function of a
highly specialized T-cell subpopulation
which remains intact after thymectomy
(Gillette and Fox, 1975).
Removal of the thymus in AKR mice
is known to reduce drastically the spon-
taneous leukaemia incidence (McEndy,
Boon and Furth, 1944). This was con-
firmed in the present experiment. But
when phorbol was injected to the thvmec-
tomized mice, lymphatic leukaemias oc-
curredinafairlyhighpercentage,especially
in the males. Greenberg and Zatz (1975)
have reported a few cases of spontaneous
lymphoma in AKR mice older than one
year, which had been thymectomized at
one month of age. These leukaemias
showed B-cell characteristics, which might
be explained by the in vivo transformation
and differentiation of the lymphoid cells
into a double-marker cell population.
These alternative suggestions to ex-
plain the strain differences in phorbol
leukaemogenesis and the effect ofthymec-
tomy in the present system should provide
a lead to further experimental exploration.
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